Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy

Authors not listed

National Taiwan University Hospital · 2018

Abstract

By combination of plasma (Aβ40, Aβ42, total tau, and phosphorylated tau, etc.), genetic (ApoE ε2 or ε4 allele), MRI (cerebral perfusion, microbleeds, cortical superficial siderosis, enlarged perivascular space, etc.) and PET imaging (amyloid and tau) biomarkers, the study aims to 1. Enhance the diagnostic potentials of the radiological biomarkers by combining MRI and amyloid PET in CAA patients. 2. Investigate the biological pathogenesis in CAA patients using the less invasive plasma biomarkers and to correlate with structural and function imaging, including MRI, amyloid and tau imaging. 3. Study the characteristics of long-term progression of amyloid deposition in CAA patients using the radiological, biochemical and genetic biomarkers. 4. Study the prognosis predicting markers.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2018). Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy. <em>National Taiwan University Hospital</em>. https://clinicaltrials.gov/study/NCT03969732
Vancouver
Anonymous. Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy. National Taiwan University Hospital. 2018.
BibTeX
@misc{anon2018Multim, title = {Multimodal Biomarkers for Diagnosis and Prognosis in Cerebral Amyloid Angiopathy}, author = {Anonymous}, journal = {National Taiwan University Hospital}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings